Late complications and quality of life after multivisceral surgeries with pancreatoduodenectomy

Egorov VI, Kotelnikov AG, Patyutko YuI, Podluzhnyi DV, Polyakov AN, Kudashkin NE, Fayazov EN. Late complications and quality of life after multivisceral surgeries with pancreatoduodenectomy. Pirogov Russian Journal of Surgery. 2025;(7):36‑45. (In Russ., In Engl.)
https://doi.org/10.17116/hirurgia202507136

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To investigate late complications after pancreatoduodenectomy (PD) as a part of multivisceral surgeries (MVS) and the impact of these interventions on the quality of life.

MATERIAL AND METHODS

Analysis of complications in long-term postoperative period included 776 patients (233 cases of MVS with PD (main group) and 543 cases of standard PD (comparison group)). Analysis of the quality of life included 58 patients from the main group and 67 patients from the comparison group. The quality of life was studied using the Russian-language versions of the EORTC QLQ-C30 and EORTC QLQ-PAN26 questionnaires.

RESULTS. T

Here were no significant between-group differences in the incidence of long-term postoperative complications (26.2% versus 20.1%, p=0.059). Diabetes mellitus occurred in 26 (15.9%) and 57 (10.8%) patients, respectively (p=0.08). Malnutrition (10.3% versus 3%, p<0.001), cholangitis (7.3% versus 2.5%, p=0.003) and edema/ascites (7.3% versus 0.8%, p<0.001) were significantly more common in the main group. According to the EORTC QLQ-C30 scores in the main group, general health (58 (58 — 58) versus 66 (58 — 66), p<0.001, weak clinical significance) and physical functions (79.5 (73 — 89) versus 86 (73 — 93), p=0.04, weak clinical significance) were significantly worse, and weakness was more pronounced (22 (22 — 33) versus 11 (11 — 22), p<0.001, moderate clinical significance). According to the EORTC QLQ-PAN26 scores, weight loss (24.5 (16—33) versus 16 (0—16), p<0.001, weak clinical significance), weakness in arms and legs (16 (16—16) versus 0 (0—16), p<0.001, moderate clinical significance) and dry mouth (8 (0—16) versus 0 (0—16), p=0.004, weak clinical significance) were more common in the main group.

CONCLUSION

MVS with PD is significantly more often accompanied by cholangitis and symptoms of alimentary failure in long-term period. This determines the worst quality of life after MVS with PD.

Keywords:

pancreatoduodenectomy

quality of life

postoperative complications

malnutrition

cholangitis

diabetes mellitus

Authors:

Egorov V.I.

Blokhin National Cancer Research Center;
Kazan State Medical University;
Republican Clinical Oncological Dispensary

ORCID: 0000-0002-6603-1390

Kotelnikov A.G.

Blokhin National Medical Cancer Research Center

ORCID: 0000-0002-2811-0549

Patyutko Yu.I.

Blokhin National Medical Research Center of Oncology

RSCI AuthorID: 137980
Scopus AuthorID: 55666204300
ORCID: 0000-0001-9254-1346

Podluzhnyi D.V.

Blokhin National Medical Cancer Research Center

ORCID: 0000-0001-7375-3378

Polyakov A.N.

Blokhin National Medical Research Center of Oncology

SPIN RSCI: 9924-0256
Scopus AuthorID: 57190413973
ORCID: 0000-0001-5348-5011

Kudashkin N.E.

Blokhin National Medical Cancer Research Center

SPIN RSCI: 3574-8344
Scopus AuthorID: 54885375500
ORCID: 0000-0003-0504-585X

Fayazov E.N.

Republican Clinical Oncological Dispensary

ORCID: 0000-0002-5217-7276

Received:

18.12.2024

Accepted:

03.02.2025

Close metadata

References:

Kotelnikov AG, Patyutko YI, Podluzhnyi DV, Saakyan MS, Kushlinski NE, Lubimova NV, Timofeev YS, Shakhbazyan RG, Polyakov AN, Kudashki NE, Tikhonov PA, Stilidi IS. Functional outcomes of pancreaticoduodenoctomy. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2023;28(1):71-79. (In Russ.). https://doi.org/10.16931/1995-5464.2023-1-71-79
Jung W, Kim H, Kwon W, Jang JY. Atrophy of remnant pancreas after pancreatoduodenectomy: Risk factors and effects on quality of life, nutritional status, and pancreatic function. J Hepatobiliary Pancreat Sci. 2022;29(2):239-249. https://doi.org/10.1002/jhbp.949
Laitinen I, Sand J, Peromaa P, Nordback I, Laukkarinen J. Quality of life in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy. Pancreatology. 2017;17(3):445-450. https://doi.org/10.1016/j.pan.2017.02.013
Balzano G, Pecorelli N, Piemonti L, Ariotti R, Carvello M, Nano R, Braga M, Staudacher C. Relaparotomy for a pancreatic fistula after a pancreaticoduodenectomy: a comparison of different surgical strategies. HPB (Oxford). 2014;16(1):40-45. https://doi.org/10.1111/hpb.12062
van Dijk SM, Heerkens HD, Tseng DSJ, Intven M, Molenaar IQ, van Santvoort HC. Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer. HPB (Oxford). 2018;20(3):204-215. https://doi.org/10.1016/j.hpb.2017.11.002
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376. https://doi.org/10.1093/jnci/85.5.365
Fong ZV, Sekigami Y, Qadan M, Fernandez-Del Castillo C, Warshaw AL, Lillemoe KD, Ferrone CR. Assessment of the Long-Term Impact of Pancreatoduodenectomy on Health-Related Quality of Life Using the EORTC QLQ-PAN26 Module. Ann Surg Oncol. 2021;28(8):4216-4224. https://doi.org/10.1245/s10434-021-09853-8
Yin T, Wen J, Zhen T, Liao Y, Zhang Z, Zhu H, Wang M, Pan S, Guo X, Zhang H, Qin R. Long-term quality of life between duodenum-preserving pancreatic head resection and pancreatoduodenectomy: a systematic review and meta-analysis. Int J Surg. 2024;110(2):1139-1148. https://doi.org/10.1097/JS9.0000000000000879
Fong ZV, Alvino DM, Castillo CF, Nipp RD, Traeger LN, Ruddy M, Lubitz CC, Johnson CD, Chang DC, Warshaw AL, Lillemoe KD, Ferrone CR. Health-related Quality of Life and Functional Outcomes in 5-year Survivors After Pancreaticoduodenectomy. Ann Surg. 2017;266(4):685-692. https://doi.org/10.1097/SLA.0000000000002380
Brown JA, Zenati MS, Simmons RL, Al Abbas AI, Chopra A, Smith K, Lee KKW, Hogg ME, Zeh HJ, Paniccia A, Zureikat AH. Long-Term Surgical Complications After Pancreatoduodenectomy: Incidence, Outcomes, and Risk Factors. J Gastrointest Surg. 2020;24(7):1581-1589. https://doi.org/10.1007/s11605-020-04641-3
Bock EA, Hurtuk MG, Shoup M, Aranha GV. Late complications after pancreaticoduodenectomy with pancreaticogastrostomy. J Gastrointest Surg. 2012;16(5):914-919. https://doi.org/10.1007/s11605-011-1805-2
Pathanki AM, Attard JA, Bradley E, Powell-Brett S, Dasari BVM, Isaac JR, Roberts KJ, Chatzizacharias NA. Pancreatic exocrine insufficiency after pancreaticoduodenectomy: Current evidence and management. World J Gastrointest Pathophysiol. 2020;11(2):20-31. https://doi.org/10.4291/wjgp.v11.i2.20
Gianotti L, Besselink MG, Sandini M, Hackert T, Conlon K, Gerritsen A, Griffin O, Fingerhut A, Probst P, Abu Hilal M, Marchegiani G, Nappo G, Zerbi A, Amodio A, Perinel J, Adham M, Raimondo M, Asbun HJ, Sato A, Takaori K, Shrikhande SV, Del Chiaro M, Bockhorn M, Izbicki JR, Dervenis C, Charnley RM, Martignoni ME, Friess H, de Pretis N, Radenkovic D, Montorsi M, Sarr MG, Vollmer CM, Frulloni L, Büchler MW, Bassi C. Nutritional support and therapy in pancreatic surgery: A position paper of the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2018;164(5):1035-1048. https://doi.org/10.1016/j.surg.2018.05.040
Roberts KJ, Schrem H, Hodson J, Angelico R, Dasari BVM, Coldham CA, Marudanayagam R, Sutcliffe RP, Muiesan P, Isaac J, Mirza DF. Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy. HPB (Oxford). 2017;19(10):859-867. https://doi.org/10.1016/j.hpb.2017.05.009
Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A, Clavien PA. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(15):2526-2531. https://doi.org/10.1200/JCO.2007.15.5556
Roberts KJ, Bannister CA, Schrem H. Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study. Pancreatology. 2019;19(1):114-121. https://doi.org/10.1016/j.pan.2018.10.010
Phillips ME. Pancreatic exocrine insufficiency following pancreatic resection. Pancreatology. 2015;15(5):449-455. https://doi.org/10.1016/j.pan.2015.06.003
Ito T, Sugiura T, Okamura Y, Yamamoto Y, Ashida R, Aramaki T, Endo M, Matsubayashi H, Ishiwatari H, Uesaka K. Late benign biliary complications after pancreatoduodenectomy. Surgery. 2018;163(6): 1295-1300. https://doi.org/10.1016/j.surg.2018.02.015